Eli Lilly and Company (LLY)vsNeOnc Technologies Holdings, Inc. Common Stock (NTHI)
LLY
Eli Lilly and Company
$1,185.71
-0.52%
HEALTHCARE · Cap: $1.02T
NTHI
NeOnc Technologies Holdings, Inc. Common Stock
$3.50
0.00%
HEALTHCARE · Cap: $90.50M
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
NTHI
Avoid15
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 34.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : NTHI
The strongest argument for NTHI centers on Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, P/E Ratio, Debt/Equity.
Bear Case : NTHI
The primary concerns for NTHI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while NTHI is a value play — different risk/reward profiles.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 15/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →NeOnc Technologies Holdings, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy and molecular medicine initiatives. The company boasts a compelling pipeline of innovative product candidates aimed at addressing critical unmet needs within oncology, which positions it as a potential leader in the evolution of cancer care. Backed by strategic partnerships within the biopharmaceutical sector, NeOnc has the capability to accelerate the commercialization of its groundbreaking therapies, presenting a compelling opportunity for institutional investors interested in the expanding cancer therapeutics market.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?